Recall initiated for Nature's Own Glucosamine Sulfate with Chondroitin (batch 1662937) and Nature's Own Magnesium Glycinate 1150mg (batch 1665576) due to glass fragments.
Glass fragments can cause injury when handling product or harm if accidentally swallowed, requiring immediate consumer action.
Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.
Regulatory Intelligence Lead
one-time
Consumers should stop using the product and return it to the place of purchase for a full refund.
Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.
Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare is recalling two products due to potential glass fragments in the bottle, posing cut and ingestion hazards.
What changed: Recall initiated for Nature's Own Glucosamine Sulfate with Chondroitin (batch 1662937) and Nature's Own Magnesium Glycinate 1150mg (batch 1665576) due to glass fragments.
Why it matters: Glass fragments can cause injury when handling product or harm if accidentally swallowed, requiring immediate consumer action.
Practical implication: Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.
Published from the Firecrawl agent regulatory extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
